B-type natriuretic peptide efficacy compared to fragmented QRS for diastolic dysfunction screening in patients with type 2 diabetes

Table 3 Multivariate model analysis on the diastolic dysfunction diagnosis in overweight participants

Factors	OR	95%CI	P value
Model 1; AIC: 128.79
Age, 10-year increments	2.22	1.43-3.71	< 0.001
Sex, male/female	1.06	0.41-2.79	0.908
CAD	0.30	0.07-1.01	0.068
sBP, every 10 mmHg	1.66	0.72-2.30	< 0.001
HR, every 10/minute	1.91	1.29-2.99	0.002
BNP, per SD	1.19	0.77-1.82	0.387
Model 2; AIC: 114.95
Age, 10-year increments	2.60	1.57-4.77	< 0.001
Sex, male/female	0.87	0.30-2.48	0.790
CAD	0.18	0.03-0.71	0.024
sBP, every 10 mmHg	1.75	1.28-2.51	< 0.001
HR, every 10/minute	1.82	1.18-2.96	0.010
fQRS	7.15	2.55-22.4	< 0.001
Model 3; AIC: 116.52
Age, 10-year increments	2.57	1.55-4.72	< 0.001
Sex, male/female	0.87	3.03-2.48	0.789
CAD	0.17	0.03-0.69	0.022
sBP, every 10 mmHg	1.73	1.27-2.48	0.001
HR, every 10/minute	1.87	1.21-3.05	0.008
BNP, per SD	1.16	0.71-1.78	0.497
fQRS	7.07	2.51-22.2	< 0.001

OR: Odds ratio; CI: Confidence interval; AIC: Akaike’s information criterion; BNP: Brain natriuretic peptide; CAD: Coronary artery disease; fQRS: Fragmented QRS; HR: Heart rate; sBP: Systolic blood pressure.